2022
Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease
Mosher CL, Nanna MG, Jawitz OK, Raman V, Farrow NE, Aleem S, Casaburi R, MacIntyre NR, Palmer SM, Myers ER. Cost-effectiveness of Pulmonary Rehabilitation Among US Adults With Chronic Obstructive Pulmonary Disease. JAMA Network Open 2022, 5: e2218189. PMID: 35731514, PMCID: PMC9218844, DOI: 10.1001/jamanetworkopen.2022.18189.Peer-Reviewed Original ResearchConceptsQuality-adjusted life expectancyNet cost savingsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness ratioEconomic evaluationSocietal perspective analysisCost savingsSensitivity analysisChronic obstructive pulmonary diseaseMarkov microsimulation modelUS dollarsMicrosimulation modelNet costDominant strategySocietal perspectiveLifetime horizonUS health care systemPulmonary rehabilitationObstructive pulmonary diseaseCOPD hospitalizationsHypothetical cohortQALYSavingsMicrosimulation
2021
On All Accounts: Cost-Effectiveness Analysis of Limited Preoperative Optimization Efforts Before Colon Cancer Surgery
Leeds IL, Drabo EF, Lehmann LS, Safar B, Johnston FM. On All Accounts: Cost-Effectiveness Analysis of Limited Preoperative Optimization Efforts Before Colon Cancer Surgery. Diseases Of The Colon & Rectum 2021, 64: 744-753. PMID: 33955409, PMCID: PMC8835996, DOI: 10.1097/dcr.0000000000001926.Peer-Reviewed Original ResearchConceptsCost-effectiveness analysisProbabilistic sensitivity analysesNet monetary benefitIncremental cost-effectiveness ratioTotal costCost-effectiveness ratioMonetary benefitsSensitivity analysisBreakeven costDominant strategyEconomic costsDecision analysis methodologyCostHypothetical scenariosAlto riesgoEl análisisAnálisisEconómicoBenefitsAnalysis methodologyReducciónCost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer
Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open 2021, 4: e2033787. PMID: 33439266, PMCID: PMC7807293, DOI: 10.1001/jamanetworkopen.2020.33787.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerMetastatic hormone-sensitive prostate cancerProstate radiation therapyEconomic evaluationProstate cancerHealth-state utility estimatesIncremental cost-effectiveness ratioRadiation therapyLow-volume metastatic hormone-sensitive prostate cancerProbabilistic sensitivity analysesLow burden metastatic prostate cancerLow-volume metastatic prostate cancerCost-effectiveness ratioHormone-sensitive prostate cancerDominant treatment strategyBase case scenarioFailure-free survivalUS dollarsNet costUtility estimatesDominant strategyCost-effective treatmentHigher QALYsQALYDeprivation therapy
2015
Evaluation for Blunt Cerebrovascular Injury: Review of the Literature and a Cost-Effectiveness Analysis
Malhotra A, Wu X, Kalra VB, Schindler J, Matouk CC, Forman HP. Evaluation for Blunt Cerebrovascular Injury: Review of the Literature and a Cost-Effectiveness Analysis. American Journal Of Neuroradiology 2015, 37: 330-335. PMID: 26450540, PMCID: PMC7959958, DOI: 10.3174/ajnr.a4515.Peer-Reviewed Original ResearchConceptsCost-effective imaging strategyNet monetary benefitHealth care payer perspectiveIncremental cost-effectiveness ratioCare payer perspectiveCost-effectiveness analysisCost-effective strategyCost-effectiveness ratioEconomic evaluationMonetary benefitsDominant strategyMain indicatorsPayer perspectiveSelective DSAComparable utilityUtility perspectiveDecision tree analysisSelective anticoagulationSensitivity analysisCostImmense controversyHigh costCTA sensitivityParameter valuesHorizon
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply